Products

Bioceros is building a pipeline of early-phase promising proprietary therapeutic monoclonal antibodies, including targets in oncology and auto-immune disease.

The company employs its validated technology platforms and pre-clinical development expertise to design and develop effective humanised monoclonal antibodies.

Bioceros B.V. is actively seeking early-stage monoclonal antibody product candidates in the field of cancer and (auto)-immune diseases for either in-licensing or to jointly develop these antibodies.

If you want to learn more about this opportunity, please contact:
Louis Boon, Ph.D.
Chief Scientific Officer
Tel.: +31 30 253 7521 or +31 6 25026350
l.boon@bioceros.com